Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Bowen's disease (squamous cell carcinoma in situ), drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Nobody knows how common it is. Carcinoma in situ of the skin sits outside the non-melanoma skin cancer totals, and those totals are themselves counted on a rule that misses repeat tumours, so there is no dependable national figure for a diagnosis many thousands of people are given every year.
The 3 to 5 percent who progress cannot be identified in advance. There is no marker that separates the lesion that will become invasive from the one that will not, so everybody is treated, and most of that treatment is for lesions that would never have caused harm.
The lower leg is the commonest site and the hardest to treat, because wounds there heal slowly in the people who most often have the disease. The evidence base for choosing between the destructive treatments at that site is thin.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 2 changes by month →When this page itself was last checked or edited.
Topical fluorouracil or imiquimod, cryotherapy, curettage and cautery, photodynamic therapy, surgical excision, Mohs surgery, radiotherapy or laser; Cancer Research UK states that all of these can work well and that cure rates are high. The choice is driven by the site, the size, how well the skin there heals and what the person can manage at home. The treatment layer of this family carries the detail.